AMY2A, amylase alpha 2A, 279

N. diseases: 21; N. variants: 0
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0162565
Disease: Acute intermittent porphyria
Acute intermittent porphyria
0.020 Biomarker disease BEFREE Seven out of 10 clones were amylase alpha-2A, the autoantibody to which was specifically detected in sera from patients with AIP and fulminant type 1 diabetes (FT1DM) [T. Endo, S. Takizawa, S. Tanaka, M. Takahashi, H. Fujii, T. Kamisawa, T. Kobayashi, Amylase alpha-2A autoantibodies: novel marker of autoimmune pancreatitis and fulminant type 1 diabetes mellitus, Diabetes 58 (2009) 732-737]. 19520060 2009
CUI: C0162565
Disease: Acute intermittent porphyria
Acute intermittent porphyria
0.020 Biomarker disease BEFREE These results suggest that an autoantibody against amylase alpha-2A is a novel diagnostic marker for both AIP and fulminant type 1 diabetes and that, clinically and immunologically, AIP and fulminant type 1 diabetes are closely related. 19001184 2009
CUI: C1279945
Disease: Acute interstitial pneumonia
Acute interstitial pneumonia
0.020 Biomarker disease BEFREE Seven out of 10 clones were amylase alpha-2A, the autoantibody to which was specifically detected in sera from patients with AIP and fulminant type 1 diabetes (FT1DM) [T. Endo, S. Takizawa, S. Tanaka, M. Takahashi, H. Fujii, T. Kamisawa, T. Kobayashi, Amylase alpha-2A autoantibodies: novel marker of autoimmune pancreatitis and fulminant type 1 diabetes mellitus, Diabetes 58 (2009) 732-737]. 19520060 2009
CUI: C1279945
Disease: Acute interstitial pneumonia
Acute interstitial pneumonia
0.020 Biomarker disease BEFREE These results suggest that an autoantibody against amylase alpha-2A is a novel diagnostic marker for both AIP and fulminant type 1 diabetes and that, clinically and immunologically, AIP and fulminant type 1 diabetes are closely related. 19001184 2009
CUI: C2609129
Disease: Autoimmune pancreatitis
Autoimmune pancreatitis
0.020 Biomarker disease BEFREE Seven out of 10 clones were amylase alpha-2A, the autoantibody to which was specifically detected in sera from patients with AIP and fulminant type 1 diabetes (FT1DM) [T. Endo, S. Takizawa, S. Tanaka, M. Takahashi, H. Fujii, T. Kamisawa, T. Kobayashi, Amylase alpha-2A autoantibodies: novel marker of autoimmune pancreatitis and fulminant type 1 diabetes mellitus, Diabetes 58 (2009) 732-737]. 19520060 2009
CUI: C2609129
Disease: Autoimmune pancreatitis
Autoimmune pancreatitis
0.020 Biomarker disease BEFREE Amylase alpha-2A autoantibodies: novel marker of autoimmune pancreatitis and fulminant type 1 diabetes. 19001184 2009
Autosomal dominant retinitis pigmentosa
0.010 GeneticVariation disease BEFREE A statistically significant lod score of 3.9 is obtained for the RP locus and AMY2 at a recombination frequency of 1%. 879170 1977
CUI: C0007095
Disease: Carcinoid Tumor
Carcinoid Tumor
0.010 Biomarker phenotype BEFREE Nucleotide sequence analysis showed that the amylase expressed in this carcinoid tumor has 13 and 6 amino acid substitutions when compared with salivary amylase (Amy1) and pancreatic amylase (Amy2), respectively. 2701942 1989
CUI: C0334299
Disease: Carcinoid tumor no ICD-O subtype
Carcinoid tumor no ICD-O subtype
0.010 Biomarker phenotype BEFREE Nucleotide sequence analysis showed that the amylase expressed in this carcinoid tumor has 13 and 6 amino acid substitutions when compared with salivary amylase (Amy1) and pancreatic amylase (Amy2), respectively. 2701942 1989
CUI: C0011847
Disease: Diabetes
Diabetes
0.010 Biomarker disease BEFREE Seven out of 10 clones were amylase alpha-2A, the autoantibody to which was specifically detected in sera from patients with AIP and fulminant type 1 diabetes (FT1DM) [T. Endo, S. Takizawa, S. Tanaka, M. Takahashi, H. Fujii, T. Kamisawa, T. Kobayashi, Amylase alpha-2A autoantibodies: novel marker of autoimmune pancreatitis and fulminant type 1 diabetes mellitus, Diabetes 58 (2009) 732-737]. 19520060 2009
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus
0.010 Biomarker group BEFREE Seven out of 10 clones were amylase alpha-2A, the autoantibody to which was specifically detected in sera from patients with AIP and fulminant type 1 diabetes (FT1DM) [T. Endo, S. Takizawa, S. Tanaka, M. Takahashi, H. Fujii, T. Kamisawa, T. Kobayashi, Amylase alpha-2A autoantibodies: novel marker of autoimmune pancreatitis and fulminant type 1 diabetes mellitus, Diabetes 58 (2009) 732-737]. 19520060 2009
Diabetes Mellitus, Insulin-Dependent
0.020 Biomarker disease BEFREE Seven out of 10 clones were amylase alpha-2A, the autoantibody to which was specifically detected in sera from patients with AIP and fulminant type 1 diabetes (FT1DM) [T. Endo, S. Takizawa, S. Tanaka, M. Takahashi, H. Fujii, T. Kamisawa, T. Kobayashi, Amylase alpha-2A autoantibodies: novel marker of autoimmune pancreatitis and fulminant type 1 diabetes mellitus, Diabetes 58 (2009) 732-737]. 19520060 2009
Diabetes Mellitus, Insulin-Dependent
0.020 Biomarker disease BEFREE These results suggest that an autoantibody against amylase alpha-2A is a novel diagnostic marker for both AIP and fulminant type 1 diabetes and that, clinically and immunologically, AIP and fulminant type 1 diabetes are closely related. 19001184 2009
Diabetes Mellitus, Non-Insulin-Dependent
0.040 Biomarker disease BEFREE We found potent pancreatic α-amylase inhibition in Astilbe thunbergii root extract (AT) and confirmed that AT treatment in a T2DM rat model reduces post-starch administration blood glucose levels. 28743229 2017
Diabetes Mellitus, Non-Insulin-Dependent
0.040 Biomarker disease BEFREE The acylated flavonol glycoside montbretin A (MbA) and its precursor myricetin 3-<i>O</i>-(6'-<i>O</i>-caffeoyl)-glucosyl rhamnoside (mini-MbA) are potent inhibitors of human pancreatic α-amylase and are being developed as drug candidates to treat type-2 diabetes. 29967287 2018
Diabetes Mellitus, Non-Insulin-Dependent
0.040 AlteredExpression disease BEFREE These animals are also a source of pancreatic α-amylase inhibitors, which have the ability to control the glucose level in the blood and can be used for the treatment of prediabetes and type 2 diabetes mellitus. 31546678 2019
Diabetes Mellitus, Non-Insulin-Dependent
0.040 Biomarker disease BEFREE Structures of human pancreatic α-amylase in complex with acarviostatins: Implications for drug design against type II diabetes. 21111049 2011
CUI: C3495814
Disease: Fulminant type 1 diabetes mellitus
Fulminant type 1 diabetes mellitus
0.010 Biomarker disease BEFREE Seven out of 10 clones were amylase alpha-2A, the autoantibody to which was specifically detected in sera from patients with AIP and fulminant type 1 diabetes (FT1DM) [T. Endo, S. Takizawa, S. Tanaka, M. Takahashi, H. Fujii, T. Kamisawa, T. Kobayashi, Amylase alpha-2A autoantibodies: novel marker of autoimmune pancreatitis and fulminant type 1 diabetes mellitus, Diabetes 58 (2009) 732-737]. 19520060 2009
CUI: C0221773
Disease: Hyperamylasemia
Hyperamylasemia
0.010 GeneticVariation disease BEFREE Coexpression of the AMY1 gene and AMY2 gene (pancreatic type) was observed in most of the lung cancers without hyperamylasemia, lung tissue, and cells scraped from the tracheal epithelium, thyroid, and female genital tract (ovary, fallopian tube, and uterus cervix), while minimal levels of mRNA transcripts of the AMY2 gene were detected in other malignant neoplasms, various normal tissues, and the cultured cell lines. 7507116 1994
CUI: C0020456
Disease: Hyperglycemia
Hyperglycemia
0.030 Biomarker disease BEFREE Astilbe thunbergii reduces postprandial hyperglycemia in a type 2 diabetes rat model via pancreatic alpha-amylase inhibition by highly condensed procyanidins. 28743229 2017
CUI: C0020456
Disease: Hyperglycemia
Hyperglycemia
0.030 Biomarker disease BEFREE In this study, the inhibitory effects of loquat leaf extract (LLE) on pancreatic α-amylase and α-glucosidase, and the preventative effects of LLE on hyperlipidemia and hyperglycemia in rats induced by a high fat and fructose diet have been evaluated. 28124052 2017
CUI: C0020456
Disease: Hyperglycemia
Hyperglycemia
0.030 AlteredExpression disease BEFREE Intestinal and pancreatic α-amylase and α-glucosidase inhibitors offer an approach to lower the levels of post-prandial hyperglycemia through the control of dietary starch breakdown in digestion. 28170007 2017
CUI: C0020473
Disease: Hyperlipidemia
Hyperlipidemia
0.010 Biomarker disease BEFREE In this study, the inhibitory effects of loquat leaf extract (LLE) on pancreatic α-amylase and α-glucosidase, and the preventative effects of LLE on hyperlipidemia and hyperglycemia in rats induced by a high fat and fructose diet have been evaluated. 28124052 2017
CUI: C0751783
Disease: Lafora Disease
Lafora Disease
0.010 Biomarker disease BEFREE We report studies on the efficacy and CNS delivery of VAL-0417, an antibody-enzyme fusion composed of the 3E10 hFab and human pancreatic α-amylase, in a mouse model of LD. 31329461 2019
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung
0.010 GeneticVariation disease BEFREE Coexpression of the AMY1 gene and AMY2 gene (pancreatic type) was observed in most of the lung cancers without hyperamylasemia, lung tissue, and cells scraped from the tracheal epithelium, thyroid, and female genital tract (ovary, fallopian tube, and uterus cervix), while minimal levels of mRNA transcripts of the AMY2 gene were detected in other malignant neoplasms, various normal tissues, and the cultured cell lines. 7507116 1994